Table 4.
Pharmacokinetic parameters of myricetin in DSS-group mice and normal-group mice after oral administration of M10 at a dose of 50 mg/kg (mean ± SD, n = 3).
| Tissue | Cmax | Tmax | AUC0–t | |||
|---|---|---|---|---|---|---|
| DSS Group | Normal Group | DSS Group | Normal Group | DSS Group | Normal Group | |
| Colon | 540.55 ± 45.01 * | 438.37 ± 20.56 | 3.33 ± 1.16 | 1.50 ± 0.87 | 3066.05 ± 84.60 ** | 2362.76 ± 244.96 |
| Stomach | 1345.17 ± 797.72 | 1541.88 ± 1023.32 | 6.00 ± 2.00 | 2.06 ± 3.42 | 4510.22 ± 2033.43 | 3168.06 ± 1056.16 |
| Small Intestine | 6165.64 ± 4951.21 | 3412.09 ± 2154.23 | 0.08 ± 0.00 | 0.08 ± 0.00 | 4764.72 ± 960.37 * | 2701.90 ± 999.18 |
*p < 0.05, **p < 0.01 compared with normal-group mice.